Evidence map›Paper›PMID 41584360›Full record

ArticleActa pharmaceutica Sinica. B2026

Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma.

Deby Fajar Mardhian, Kunal P Pednekar, Ahmed G Hemdan, Praneeth Reddy Kuninty, Saadia A Karim, Sabine de Winter, Josbert M Metselaar, Jennifer P Morton, Jai Prakash

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Deby Fajar MardhianEngineered Therapeutics Group, Department of Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente, Enschede 7500AE, The Netherlands.
Kunal P PednekarEngineered Therapeutics Group, Department of Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente, Enschede 7500AE, The Netherlands.
Ahmed G HemdanEngineered Therapeutics Group, Department of Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente, Enschede 7500AE, The Netherlands.
Praneeth Reddy KunintyEngineered Therapeutics Group, Department of Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente, Enschede 7500AE, The Netherlands.
Saadia A KarimCRUK Scotland Institute, Glasgow G61 1BD, UK.
Sabine de WinterEngineered Therapeutics Group, Department of Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente, Enschede 7500AE, The Netherlands.
Josbert M MetselaarScarTec Therapeutics BV, Horst 2, Enschede 7522LW, The Netherlands.
Jennifer P MortonCRUK Scotland Institute, Glasgow G61 1BD, UK.
Jai PrakashEngineered Therapeutics Group, Department of Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente, Enschede 7500AE, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor-stroma interaction contributes to the aggressive and resistance nature of pancreatic ductal adenocarcinoma (PDAC), leading to treatment failure. Cancer-associated fibroblasts (CAFs), a key cell type in the stroma, produce abundant extracellular matrix (ECM) and exhibit crosstalk with cancer cells inducing chemoresistance. In this study, we designed a cyclic peptide (cyAV3.3) targeting integrin

Indexed as

Cancer-associated fibroblastscyAV3.3FibronectinITGA5Pancreatic cancerPancreatic stellate cellsPeptideTumor microenvironment

Identifiers

PMID41584360
PMCPMC12828148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.